Diabetes Dialogue: Upcoming Upgrades for Omnipod Technology

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down what Insulet Corporation’s announcements surrounding forthcoming updates to Omnipod mean for the diabetes community.

At its 2025 Innovation Showcase, Insulet Corporation highlighted a series of major product advancements that are expected to significantly expand the clinical utility of automated insulin delivery (AID) for both type 1 and type 2 diabetes. The company outlined 3 sequential product launches between 2026 and 2028, each designed to simplify therapy, enhance glycemic outcomes, and broaden access to AID across diverse clinical settings.

Omnipod 5 Enhancements (Expected 2026)

Pending FDA clearance, Insulet plans upgrades to the current Omnipod 5 system, which became the first FDA-approved AID system for type 2 diabetes in August 2024, to strengthen glycemic control, improve usability, and expand ecosystem connectivity. Key clinical-facing improvements include:

• Full interoperability with all major continuous glucose monitoring (CGM) systems.
• Improved algorithmic performance designed to optimize time-in-range and reduce hypoglycemia.
• Omnipod Discover, a new machine-learning insights platform, intended to streamline onboarding, simplify dose adjustment, and support clinical decision-making with real-time, data-driven recommendations.

Omnipod 6 (Expected 2027)

Insulet’s next AID platform, Omnipod 6, introduces a redesigned system built to elevate both personalization and simplicity:

• An adaptive insulin-dosing algorithm that continuously learns and adjusts to each user’s glucose patterns.
• A configurable Pod engineered to function with any CGM system on the market.
• A new app and controller interface emphasizing intuitive setup, patient autonomy, and reduced clinic training burden.

Omnipod 6 is intended for use in both type 1 and type 2 diabetes, expanding AID applicability to the large population of insulin-requiring type 2 patients who have had limited access to pump therapy.

Omnipod Fully Closed Loop for Type 2 Diabetes (Expected 2028)

Insulet also announced plans for the Omnipod Fully Closed Loop for Type 2, which is designed as the first out-of-the-box, fully automated insulin delivery system for type 2 diabetes:

• No meal announcements, carb counting, or manual boluses required
• An intelligent algorithm that autonomously manages basal and bolus insulin delivery
• Zero-setup design intended to enable prescription and use in primary care, dramatically broadening AID access

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References:

1. Insulet Corporation. Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day. Insulet.com. Published November 20, 2025. Accessed November 25, 2025. https://investors.insulet.com/news/news-details/2025/Insulet-Outlines-Long-Term-Strategy-to-Drive-Growth-and-Value-Creation-at-2025-Investor-Day/default.aspx.

2. Insulet Corporation. Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes. Insulet.com. Published August 26, 2024. Accessed November 25, 2025. https://investors.insulet.com/news/news-details/2024/Omnipod-5-Automated-Insulin-Delivery-System-is-now-FDA-cleared-for-People-with-Type-2-Diabetes/default.aspx